References

Immunotherapy in Melanoma: recent advances and future directions

10.3390/cancers15041106 · 2023 · External reference

Association of sociodemographic factors with immunotherapy receipt for metastatic melanoma in the US

10.1001/jamanetworkopen.2020.15656 · 2020 · External reference

Survival outcomes of patients with clinical stage III melanoma in the era of novel systemic therapies

10.1245/s10434-019-07599-y · 2019 · External reference

Racial and socioeconomic disparities in the delivery of immunotherapy for metastatic melanoma in the United States

10.1097/cji.0000000000000264 · 2019 · External reference

Disparities in the receipt of systemic treatment in metastatic Melanoma

10.1097/coc.0000000000001083 · 2024 · External reference

Disparities in utilization of novel cancer therapies in advanced stage III and IV melanoma and variance in outcomes

10.1080/1750743x.2025.2452836 · 2025 · External reference

Disparities of immunotherapy utilization in patients with stage III cutaneous melanoma: a national perspective

2018 · External reference

Immunotherapy treatment disparities: a Texas cancer registry analysis of patients with cutaneous melanoma

10.1007/s10903-023-01536-8 · 2024 · External reference

The ongoing racial disparities in melanoma: an analysis of the surveillance, epidemiology, and end results database (1975-2016)

10.1016/j.jaad.2020.08.097 · 2021 · External reference

Hospital case volume is associated with improved survival for patients with metastatic Melanoma

10.1097/coc.0000000000000074 · 2016 · External reference

Association between hospital volume and overall survival (OS) of stage 3 and 4 cutaneous malignant melanoma (MMel)

10.1200/jco.2018.36.15_suppl.9524 · 2018 · External reference

Association between hospital volume, therapy types, and overall survival in stage III and IV cutaneous malignant melanoma

10.6004/jnccn.2019.7320 · 2019 · External reference

Treatment of primary nonmetastatic melanoma at high-volume academic facilities is associated with improved long-term patient survival

10.1016/j.jaad.2018.10.026 · 2019 · External reference

Comparison of capture rates of the national cancer database across race and ethnicity

10.1001/jamanetworkopen.2023.50237 · 2023 · External reference

Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs

10.1001/jamanetworkopen.2019.2535 · 2019 · External reference

Racial and ethnic disparities in survival outcomes of metastatic renal cell carcinoma patients receiving immunotherapy

10.1016/j.clgc.2024.102104 · 2024 · External reference

Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: a Texas study

2022 · External reference

Unequal racial distribution of immunotherapy for late-stage non-small cell lung cancer

10.1093/jnci/djad132 · 2023 · External reference

Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States

10.1002/hep.32527 · 2022 · External reference

Melanoma and racial health disparities in black individuals-facts, fallacies, and fixes

10.1001/jamadermatol.2021.2215 · 2021 · External reference

Immunotherapy initiation at the end of life in patients with metastatic cancer in the US

10.1001/jamaoncol.2023.6025 · 2024 · External reference

Acral Melanoma in skin of color: current insights and future directions: a narrative review

10.3390/cancers17030468 · 2025 · External reference